Skip to main content
. 2022 Dec 2;7(49):45665–45677. doi: 10.1021/acsomega.2c06531

Table 2. EGFR/PARP Target Inhibition of Compounds 12b, 13a, and 13b.

  IC50 (nM)
sample EGFR PARP-1
12b 78.1 2.13
13a 140.2 21.6
13b 62.4 1.24
Erlotinib 8035  
Olaparib   1.4936